Usefulness of semiquantitative PCR‐Invader assay for selecting candidates for daclatasvir plus asunaprevir combination therapy among patients with hepatitis C virus genotype 1b

Honda, Koichi; Seike, Masataka; Oribe, Junya; Endo, Mizuki; Arakawa, Mie; Tokoro, Masanori; Iwao, Masao; Mori, Tsuneatsu; Nishimura, Junko; Takahashi, Yukou; Ômori, Kaoru; Yamashita, Tsutomu; Muro, Toyokichi; Murakami, Kazunari

doi:10.1111/hepr.12994

Cited by 2 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, a previous clinical trial using SOF/LDV resulted in a high SVR rate for genotype 1 HCV-infected adolescents, including patients with NS5A RAVs (16). Concerning RAV detection, Honda et al reported that the semiquantitative polymerase chain reaction (PCR)-Invader assay is a highly sensitive method for determining the presence of pretreatment minor NS5A variants (21). Further studies on the relationship between DAA efficacy and RAVs in children and the optimal method for determining the presence of RAVs are needed.…”

Section: Discussionmentioning

confidence: 98%

Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection

et al. 2020

View full text Add to dashboard Cite

Although direct-acting antivirals (DAAs) have significantly increased the sustained virological response (SVR) rates in chronic hepatitis C virus (HCV)-infected adult patients, the efficacy and safety for children remain unclear. We herein report three HCV-infected children who received DAA treatment. The patients were girls 10-13 years old who had been infected with genotype 1b HCV by vertical transmission based on a phylogenetic tree analysis. Two patients were treated with 12 weeks of ombitasvir/paritaprevir/ritonavir, and the other patient was treated with 8 weeks of glecaprevir/pibrentasvir. All children received DAA doses that were similar to the dosages for adult patients. None developed adverse events, and all children achieved an SVR.

show abstract

Section: Discussionmentioning

confidence: 98%

Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection

et al. 2020

View full text Add to dashboard Cite

show abstract

“…RAS detection in the NS5A region at baseline was performed by Invader assay (BML, Inc., Saitama, Japan) [13,14]. The targeted mutations included L31F/M/V and Y93H in the NS5A region.…”

Section: Invader Assaymentioning

confidence: 99%

Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection

et al. 2020

View full text Add to dashboard Cite

Background L31 and Y93 in the NS5A region of the hepatitis C virus (HCV) are the most important substitution positions associated with resistance to direct-acting antiviral (DAA) treatment. Methods We analyzed the frequency of NS5A L31M/V and Y93/H in NS5A inhibitor-naive HCV genotype 1 patients who received asunaprevir plus daclatasvir combination treatment using a conventional sequencing method and a deep sequencing method that can distinguish a single substitution at either position and a double substitution at both positions with a 0.1% detection threshold. Results The frequency of substitutions at both sites using the conventional method was very low, with 1 in 14 non-responders and 0 in 42 randomly selected responder patients. On the other hand, for the deep sequencing method, cases with double substitutions in the tandem sequence were detected in 8/14 non-responders and 1/42 responders (p<0.0001). For the conventional method, substitutions were detected at any position in 6/14 non-responders and 2/42 responders (p = 0.0019), with a clear difference between the two groups. The difference was also clear with the deep sequencing method, with 11/14 non-responders and 8/ 42 responders. Interestingly, for the deep sequencing method, the single substitution of L31

show abstract

Usefulness of semiquantitative PCR‐Invader assay for selecting candidates for daclatasvir plus asunaprevir combination therapy among patients with hepatitis C virus genotype 1b

Abstract: Treatment efficacy of DCV + ASV was extremely high among patients who were non-positive for NS5A RAVs on SQ-PI, especially for patients with negative results.

Cited by 2 publications

References 35 publications

Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection

Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection

Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection

Contact Info

Product

Resources

About